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P
ersistence of fetal microchimeric cells
may result in the development of
autoimmune thyroid diseases (AITD)
such as Hashimoto thyroiditis (HT) or
Graves disease (GD). In women, HT and
GD show an increased incidence in the
years following parturition. Although
fetal cells have already been shown to be
more common in the thyroid glands of
patients with an AITD compared with
controls, these cells haven’t been
described in blood of these patients.
Our study detected fetal cells in blood
of all patients with an AITD. Moreover,
fetal cells were immune cells potentially
capable of initiating a graft vs. host
reaction and suggest a potential role of
these cells in the pathogenesis of AITD.
Our study indicates the value and need
for further research in this field.
During pregnancy, fetal cells cross the
placenta into the maternal circulation
1,2
and can persist in the postpartum period
in tissues such as the thyroid gland.
3 The
mother becomes microchimeric.
4-6 The
persistence of these fetal cells may result
in the development of autoimmune thyr-
oid diseases (AITD)
7,8 such as Hashimoto
thyroiditis (HT) and Graves disease (GD).
In women, HT and GD are more pre-
valent between the ages of 30 and 50 y and
are often detected in the years following
parturition.
9-11 Moreover, HT and GD are
similar to graft vs. host disease occurring
after hematopoietic cell transplantation, an
iatrogenic form of chimerism.
8,12
The presence of fetal cells can be
investigated by real-time PCR or fluore-
scence in situ hybridization (FISH) using
male-specific markers in women who had
given birth to a son. While real-time PCR
only indicates the presence of fetal cells
and estimates the amount of fetal cells,
7
FISH gives an exact number.
5,6 Therefore,
data obtained by real-time PCR are hard
to compare with those obtained by FISH,
as shown by Renne et al.
5 Using real-time
PCR, the authors detected fetal micro-
chimerism in 38% of the patients with
HT, compared with 83% using FISH.
The differences might be explained by
different sensitivities of both techniques.
12
With real-time PCR, a single male cell
can be detected within a background of
100,000 female cells
13 compared with one
male cell within 2,000,000 female cells
with FISH.
14 Therefore, our study used
the latter technique to detect fetal cells in
blood of women with an AITD.
Fetal microchimerism has already been
shown to be more common in the thyroid
glands of patients with AITD compared
with controls.
4-6,15,16 Using real-time PCR,
Klintshar et al. detected fetal cells in 47%
of the thyroid glands of patients with
AITD compared with 4% of women
with nodular goiter.
4 Later, the authors
expanded the inquiry with a quantitative
PCR-based approach, amplifying the
DYS14 region of the Y chromosome, a
technique that allows greater sensitivity
because of multiple repeats.
15 This study
identified male DNA in 38% of women
with HT, in 5% of women with multi-
nodular goiter and 0% of women with
normal thyroid glands. In 20% of patients
with GD, fetal cells were detected in
paraffin-embedded thyroid tissue com-
pared with 0% in women with adenoma.
16
However, examining fresh-frozen thyroid
tissues, fetal microchimeric cells were
detected in 85% of patients with GD
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compared with 25% of patients with
adenoma, showing that paraffin-embedded
tissue is subject to DNA fragmentation.
Using FISH, Renne et al.
5 found that 60%
of women with HT, 40% of women with
GD and 22% of patients with thyroid
adenoma were positive for male fetal cells
in the thyroid. Using the same technique,
Srivatsa et al.
6 detected fetal cells in 72%
of women with an AITD compared with
0% in healthy controls.
In contrast to thyroid tissue, fetal cells
were detected in the blood of all patients
with an AITD in our study.
14 The highest
number of fetal cells was observed in
patients with GD (14 to 29 fetal cells per
million maternal cells), followed by HT
(7 to 11) compared with the low number
of fetal cells detected in healthy volunteers
(0 to 5). This indicates a higher degree of
microchimerism in AITD compared with
healthy controls (p , 0.05). Moreover,
significantly more fetal cells were detected
in patients with GD compared with
patients with HT (p = 0.0061).
14
The etiologic consequences of fetal
microchimerism are difficult to assess to
date. Up to now, only the presence of fetal
engrafted cells in AITD is proven, but not
an actual active role of microchimerism
in the autoimmune process. An argument
against an active role is that only a part
of all patients with AITD show micro-
chimerism in their thyroid.
4-6,15,16 Never-
theless, in patients who appear to be
negative, it is possible that fetal micro-
chimerism is not detectable by the
methods used or the fact that only female
fetal cells are present.
4 In our study
however, fetal cells were detected in all
patients with an AITD. Taken together,
these data suggest a potential role of these
cells in the pathogenesis of AITD.
13,17
If fetal cells indeed play a role in AITD,
it is expected that fetal cells are pluripotent
stem cells or immune cells. Male fetal
CD34+ and CD38+ progenitor cells,
capable of differentiating into immune
competent cells,
3 but also mature fetal T,
B and NK cells
18 have been isolated from
the blood of women with scleroderma,
an autoimmune disease of the skin. Cha
et al.
19 suggested that fetal progenitor cells
may differentiate in the maternal host
and might alter immune function. Fetal
immune cells may be reactive to maternal
antigens
20 and, therefore, have the capacity
to trigger graft vs. host reactions. It is
possible that fetal cells also elicit an
intrathyroidal graft vs. host reaction that
leads to AITD.
5 Ando et al.
16 and Davies
et al.
21 propose that after delivery, when
placental tolerogenic mechanisms are
lost, intrathyroidal fetal immune cells are
activated and initiate a graft vs. host reac-
tion against maternal antigens resulting in
the activation of maternal autoreactive
T cells which could eventually modulate
AITD in the postpartum.
Our study focused on the presence of
fetal B and T cells in blood of women with
an AITD because these subsets are more
likely to initiate or be involved in immune
response. In patients with HT, mainly
fetal CD8+ cytotoxic T cells were found.
14
One might speculate that these cytotoxic
T cells could cause cell death leading to
hypothyroidism.
22 In patients with GD,
the majority of fetal cells was found in the
B cell fraction.
14 These B cells could
possibly be activated by fetal CD4+
T cells, also detected in the blood of these
patients. Other cell types, not isolated
during selection of T and B cells, were
also found and are likely to be natural
killer (NK) cells or hematopoietic pro-
genitor cells capable of differentiating
into immune competent cells.
18 One
might speculate that thyroid-reactive
T cells could cause activation of thyro-
tropin receptor (TSHR)-reactive B cells,
secreting TSHR-stimulating antibodies
causing hyperthyroidism.
22 These thyroid
antibodies have already been described in
blood.
23 Our study indicates the value and
need for further research in this field.
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